GlassScriptPhysician profile
Toya Evette Turner
NPI 1699496166
$7,264.05
in general payments reported to CMS, 2019-2025
22 companies · $2,738 in 2025
The $2,738 reported for 2025 was more than what 96% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,529 · 2024: $2,997 · 2025: $2,738.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,215 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,215.21 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,027.97 | 2023-2025 | |
| Alkermes, INC. | $1,005.79 | 2023-2025 | Aristada, Lybalvi, Aristada Initio |
| Otsuka America Pharmaceutical, INC. | $788.72 | 2023-2025 | Rexulti, Nuedexta |
| Axsome Therapeutics, INC. | $635.51 | 2023-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $615.60 | 2023-2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $589.84 | 2023-2025 | Caplyta |
| Lundbeck LLC | $401.00 | 2023-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $296.02 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Corium, LLC | $295.18 | 2023-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $269.50 | 2023-2025 | Qelbree, Qelbree |
| Janssen Pharmaceuticals, INC | $267.93 | 2023-2025 | Spravato, Invega Sustenna |
| Takeda Pharmaceuticals U.S.A., INC. | $241.98 | 2024-2025 | Trintellix |
| Tris Pharma INC | $227.35 | 2024-2025 | Dyanavel Xr |
| Neurocrine Biosciences, INC. | $195.30 | 2024-2025 | Ingrezza |
| Ironshore Pharmaceuticals INC. | $106.99 | 2023-2024 | Jornay Pm |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $98.67 | 2023-2025 | Aplenzin |
| Harmony Biosciences LLC | $63.58 | 2025 | |
| Abbott Laboratories | $58.86 | 2024 | Proclaim |
| E.R. Squibb & Sons, L.L.C. | $37.83 | 2025 | Cobenfy |
| Saluda Medical Americas, INC. | $14.13 | 2025 | Evoke |
| Idorsia Pharmaceuticals US INC | $13.31 | 2024 | Quviviq |
| Merck Sharp & Dohme LLC | $12.99 | 2023 | Belsomra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Toya Turner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.